BioSpace News Archive

Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within Medigene’s end-to-end platform.

argenx announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.

CS Genetics, a privately held genomics-technology company, announced the appointment of Jeremy Preston, PhD, as Chief Executive Officer, after serving as Chief Commercial Officer for the past 14 months.

Verona Pharma plc announces 12 abstracts, including a mini symposium, and a clinical trials symposium, on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease have been accepted by the American Thoracic Society International Conference 2023.

Biophytis SA announces the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance and the upcoming arrival of Nicolas Fellmann as Chief Financial Officer as of 22 May 2022.

TAAV Biomanufacturing Solutions S.L.U. presents a new brand that supports the company’s transformation and purpose, which is to be the DNA manufacturing partner of choice for developers of recombinant adeno-associate virus technologies and thus become a fundamental part of the gene therapy industry.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that the US Food and Drug Administration has cleared its Investigational New Drug application for its second-generation DSR product for the treatment of congestive heart failure.

Hyloris Pharmaceuticals SA announces the US Food & Drug Administration has set 17 October 2023 as the date by which it expects to respond to the application regarding Maxigesic® IV.

ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.

Memo Therapeutics AG announced that the U.S. Food and Drug Administration has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.